What is the 13F Pro Quality Score for ALNY?

13F Pro ranks ALNYLAM PHARMACEUTICALS, INC. (ALNY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALNY's current score at https://13fpro.ai/company/ALNY (free sign-up required for the full ranking).

Which hedge funds own the most ALNY stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ALNY include FMR, Capital World Investors, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ALNY as soon as new 13F filings post.

Where does 13F Pro source ALNY data?

All ALNYLAM PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. ALNYLAM PHARMACEUTICALS, INC. files with the SEC under CIK 1178670. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALNY in?

ALNYLAM PHARMACEUTICALS, INC. (ALNY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ALNY's revenue?

Per ALNYLAM PHARMACEUTICALS, INC.'s latest 10-Q filed with the SEC on 2026-07-30, the biggest revenue drivers are: Net product revenues ($1.17B, +74% YoY); AMVUTTRA ($1.01B, +106% YoY); Total Rare (GIVLAARI & OXLUMO) ($141.9M, +11% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/ALNY.

What are ALNY's largest expenses?

ALNYLAM PHARMACEUTICALS, INC.'s latest 10-Q reports these as the largest expense items: Research and development ($413.1M, +28% YoY); Selling, general and administrative ($347.9M, +8% YoY); Cost of goods sold ($298.3M, +110% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is ALNY research updated on 13F Pro?

ALNY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ALNYLAM PHARMACEUTICALS, INC.(ALNY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1178670 ALNY stock profile & AI dashboard →

13F Pro Quality Score

71.4/100

Rank #183 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

84.9/100

Profitability

81.9/100

Balance Sheet

93.1/100

Earnings Quality

58.4/100

Free Cash Flow

57.0/100

Institutional Flow

46.8/100

Revenue Scale

76.4/100

Dilution Risk

16.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ALNY Scores 71/100

exact factor attribution · 2026-09-10

ALNY's composite is driven by revenue growth and profitability, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.0 pts

85th pct

Profitability

+4.8 pts

82th pct

Capital efficiency

+4.3 pts

93th pct

Scale

+4.0 pts

76th pct

Earnings growth

+1.3 pts

76th pct

Free cash flow

+1.0 pts

57th pct

Earnings quality

+0.8 pts

58th pct

Institutional flow

-0.2 pts

47th pct

Shareholder dilution

-1.7 pts

17th pct

Latest change (2026-08-01): 61 → 68 · ↑ Capital efficiency 38→86; ↑ Profit margin 56→81; despite ↓ Free cash flow 67→36

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ALNY Stock Analysis & AI Quality Score

Data updated 2026-09-10

AI stock analysis and institutional research for ALNYLAM PHARMACEUTICALS, INC. (ALNY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALNY at 71.4/100 on a 32-signal composite quality model, placing it at rank #183 of 2,961 stocks — the top 10% of the AI-ranked universe. ALNY scores in the top quartile across balance sheet strength (93.1), revenue growth (84.9), profitability (81.9). Shareholder dilution risk is elevated at 16.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ALNYLAM PHARMACEUTICALS, INC. reports quarterly revenue of $1.3B, net income of $164.5M, an operating margin of 17.9%. Top institutional holders of ALNY by reported 13-F value include FMR, Capital World Investors, BlackRock, based on the most recent SEC filings. ALNY trades on the Nasdaq exchange and files with the SEC under CIK 1178670. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALNY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALNYLAM PHARMACEUTICALS, INC. directly from SEC EDGAR. ALNYLAM PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 31 and 72 since 2021, currently 71.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about ALNYLAM PHARMACEUTICALS, INC.

Quirks, history, and lore behind ALNY — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · large-cap · listed on Nasdaq · headquartered in Cambridge, Massachusetts.
2
The Numbers
Annual revenue in the low billions of dollars, driven almost entirely by a handful of approved drugs — yet the company spent over a decade burning cash before its first product ever reached patients.
3
The History
Founded in 2002, the company was built from the ground up around a single Nobel Prize-winning biological mechanism discovered just a few years earlier: RNA interference.
4
The Secret
Its entire pipeline is built on silencing genes — using specially designed molecules to switch off the faulty genetic instructions that cause disease, rather than blocking the bad protein after the fact.
5
The Lore
Its landmark drug Onpattro was the first ever RNAi therapeutic approved anywhere in the world, making history in 2018 and validating a technology many had written off as science fiction.
6
The Giveaway
The pioneer of RNAi medicines, its approved drugs treat rare diseases like hereditary transthyretin amyloidosis — and its name is literally a portmanteau of "RNA" and "lam."

▶ Think you know your stocks? Play the Daily Ticker

What's Driving ALNY's Business? Latest 10-Q Breakdown

✓ 30/30 datapoints verified

AI-extracted from ALNYLAM PHARMACEUTICALS, INC.'s 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenue rose 67% to $1.29B as AMVUTTRA reached $1.01B (+106% YoY), producing $164.5M net income versus a $72.2M loss a year ago.

Biggest Revenue Drivers

Net product revenues$1.17B+74% YoY

Growth from AMVUTTRA driven by increased patient demand, mainly in patients with ATTR-CM in the U.S.

Royalty revenue$71.7M+79% YoY

Increased volume and rate of royalties earned from global net sales of Leqvio by Novartis

Biggest Revenue Drivers

Total revenue: $1.29B+67% YoY

Net product revenues$1.17B+74% YoY

Growth from AMVUTTRA driven by increased patient demand, mainly in patients with ATTR-CM in the U.S.

Within Net product revenues

AMVUTTRA$1.01B+106% YoY

U.S. sales of $809.1M, up 124%, following ATTR-CM approval

Total Rare (GIVLAARI & OXLUMO)$141.9M+11% YoY

Growth from an increased number of patients on GIVLAARI and OXLUMO

Royalty revenue$71.7M+79% YoY

Increased volume and rate of royalties earned from global net sales of Leqvio by Novartis

Net revenues from collaborations$47.2M-23% YoY

Lower Regeneron revenue on completed activities and wind-down of the Initial Research Term, partly offset by Roche ZENITH reimbursements

Largest Expense Items

Research and development$413.1M+28% YoY

Increased clinical trial expenses for ZENITH, TRITON-CM and TRITON-PN Phase 3 trials, partly offset by KARDIA wind-down and lower stock-based compensation

Selling, general and administrative$347.9M+8% YoY

Increased marketing investment for the global AMVUTTRA ATTR-CM launch and higher IT infrastructure costs, partly offset by lower stock-based compensation

Cost of goods sold$298.3M+110% YoY

Increased sales of AMVUTTRA and an associated increase in the blended royalty rate payable on AMVUTTRA net sales

Margins: Cost of goods sold rose to 25.4% of net product revenues from 21.1%, on higher AMVUTTRA sales and a higher blended Sanofi royalty rate; management expects that percentage to keep rising in 2026.

Watch Items from the Filing

Sanofi royalty tiers on AMVUTTRA escalate with volume: 25% of global annual net sales from $500.0M to $1.50B and 30% above $1.50B, compressing gross margin as sales scale.
October 2025 subpoena from the U.S. Attorney's Office for Massachusetts seeks documents on government price reporting for AMVUTTRA, ONPATTRO, OXLUMO and GIVLAARI; no loss contingency accrued.
AMVUTTRA is $1.01B of $1.17B net product revenues; ONPATTRO fell 65% to $18.5M, leaving revenue concentrated in one product.
Regeneron collaboration revenue fell 85% to $5.0M as the Initial Research Term expired in May 2026; no additional targets will be added to the collaboration.
If Blackstone Royalties does not receive $1.00 billion of Leqvio royalties by December 31, 2029, its royalty interest rises from 50% to 55% beginning January 1, 2030.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$1.3B

Net Income

Q2 2026

$164.5M

Operating Margin

Q2 2026

17.9%

ROIC

Q2 2026

68.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+65.2% YoY

$3.71BFY 2025

FY22 $1.04BFY23 $1.83BFY24 $2.25BFY25 $3.71B

Net Income

+212.8% YoY

$313.7MFY 2025

FY22 $-1.13BFY23 $-440.2MFY24 $-278.2MFY25 $313.7M

Operating Income

+383.6% YoY

$501.6MFY 2025

FY22 $-785.1MFY23 $-282.2MFY24 $-176.9MFY25 $501.6M

EPS (Diluted)

+206.9% YoY

$2.33FY 2025

FY22 $-9.30FY23 $-3.52FY24 $-2.18FY25 $2.33

Total Assets

+17.1% YoY

$4.97BFY 2025

FY22 $3.55BFY23 $3.83BFY24 $4.24BFY25 $4.97B

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+6405.1% YoY

$524.1MFY 2025

FY22 $-541.3MFY23 $104.2MFY24 $-8.3MFY25 $524.1M

Free Cash Flow

+1192.7% YoY

$465.4MFY 2025

FY22 $-613.3MFY23 $41.9MFY24 $-42.6MFY25 $465.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$3.71B +65.2%	$2.25B +23.0%	$1.83B +76.2%	$1.04B +22.9%	$844.3M +71.3%	$492.9M
Net Income	$313.7M +212.8%	$-278.2M +36.8%	$-440.2M +61.1%	$-1.13B -32.6%	$-852.8M +0.6%	$-858.3M
Operating Income	$501.6M +383.6%	$-176.9M +37.3%	$-282.2M +64.1%	$-785.1M -10.8%	$-708.7M +14.5%	$-828.4M
EPS (Diluted)	$2.33 +206.9%	$-2.18 +38.1%	$-3.52 +62.2%	$-9.30 -29.2%	$-7.20 +3.5%	$-7.46
Total Assets	$4.97B +17.1%	$4.24B +10.7%	$3.83B +8.0%	$3.55B -2.7%	$3.64B +6.9%	$3.41B
Total Debt	—	—	—	—	$675.7M +253.3%	$191.3M
Operating Cash Flow	$524.1M +6405.1%	$-8.3M -108.0%	$104.2M +119.2%	$-541.3M +15.6%	$-641.7M -4.3%	$-615.0M
Free Cash Flow	$465.4M +1192.7%	$-42.6M -201.5%	$41.9M +106.8%	$-613.3M +14.6%	$-718.1M -4.8%	$-685.3M

Get alerted when ALNY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ALNYLAM PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALNY

FMR LLC
$4.5B15,023,962 sh
Capital World Investors
$3.4B11,144,846 sh
BlackRock, Inc.
$3.3B10,907,675 sh
Capital Research Global Investors
$2.9B9,750,699 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.0B6,538,390 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.8B6,029,478 sh
T. Rowe Price Investment Management, Inc.
$1.7B5,642,173 sh
Invesco Ltd.
$1.1B3,754,318 sh
STATE STREET CORP
$1.1B3,555,689 sh
GEODE CAPITAL MANAGEMENT, LLC
$791.3M2,635,840 sh

Fund	Value	Shares
FMR LLC	$4.5B	15,023,962
Capital World Investors	$3.4B	11,144,846
BlackRock, Inc.	$3.3B	10,907,675
Capital Research Global Investors	$2.9B	9,750,699
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.0B	6,538,390
VANGUARD CAPITAL MANAGEMENT LLC	$1.8B	6,029,478
T. Rowe Price Investment Management, Inc.	$1.7B	5,642,173
Invesco Ltd.	$1.1B	3,754,318
STATE STREET CORP	$1.1B	3,555,689
GEODE CAPITAL MANAGEMENT, LLC	$791.3M	2,635,840

Companies Similar to ALNY

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

PODD

INSULET CORP

AI score

Very similar · 40 shared holders

BAILLIE GIFFORD & CO T. Rowe Price Investment Management, Inc.Clearbridge Investments, LLC

DXCM

DEXCOM INC

AI score

Very similar · 34 shared holders

BAILLIE GIFFORD & CO STEELHEAD PARTNERS LLC National Pension Service

UTHR

UNITED THERAPEUTICS Corp

AI score

Shared smart-money ownership · 27 shared holders

BAILLIE GIFFORD & CO Deep Track Capital, LP Robeco Institutional Asset Management B.V.

INCY

INCYTE CORP

AI score

Shared smart-money ownership · 33 shared holders

DODGE & COX Robeco Institutional Asset Management B.V.Vinva Investment Management Ltd

HALO

HALOZYME THERAPEUTICS, INC.

AI score

Similar quality profile · 21 shared holders

CONGRESS ASSET MANAGEMENT CO /MA ROYAL LONDON ASSET MANAGEMENT LTD STEELHEAD PARTNERS LLC

ONC

BeOne Medicines Ltd.

AI score

Similar quality profile · 18 shared holders

Capital World Investors Candriam S.C.A.Life Cycle Investment Partners Ltd

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Shared smart-money ownership · 34 shared holders

DODGE & COX Clearbridge Investments, LLC Vinva Investment Management Ltd

VRTX

VERTEX PHARMACEUTICALS INC / MA

AI score

Shared smart-money ownership · 39 shared holders

Capital World Investors Capital Research Global Investors Clearbridge Investments, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALNY on your watchlist

Track score changes the day ALNYLAM PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALNY a good stock to buy?

13F Pro's AI-powered analysis of ALNYLAM PHARMACEUTICALS, INC. (ALNY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALNY are available on the ALNY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALNY is classified as a large company.

Which hedge funds own ALNY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALNY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ALNYLAM PHARMACEUTICALS, INC.'s investment landscape.